External beam radiotherapy prior to 131-I-omburtamab
medulloblastoma, ependymoma
MEDULLOBLASTOMA, EPENDYMOMA
All patients had EBRT at a median time of 0.9 years (range 0.1–5.2) preceding cRIT (Supplemental Table 1). Most patients received CSI (22, 81%), with a median dose of 2340 cGy (range 2300–3960 cGy) with a boost to 5400 cGy (range 5040–6000 cGy). Ten (37%) CSI treatments were delivered with protons, all for patients with medulloblastoma. Most patients (20, 74%) received a focal course of EBRT, five of which were delivered with protons. Among patients with medulloblastoma, the maximum dose of EBRT pre-cRIT ranged from 1800 to 5000 cGy (median 3000 cGy). For ependymoma, the maximum dose of EBRT pre-cRIT ranged from 4720 to 5940 cGy (median 5700 cGy). Prior to cRIT, 15 (56%) medulloblastoma and 6 ependymoma (86%) patients received more than one course of EBRT. None of the patients received multiple courses of CSI pre-cRIT.